Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-18. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Formulary access for oral obesity candidate Foundayo across major PBMs expands commercial volume, supporting Lilly's $27.7 billion H1 GLP-1 revenue base.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in revenue in the first half of 2026. |
| What else was confirmed? | Reported factThe company's oral obesity drug Foundayo has achieved formulary coverage across major pharmacy benefit managers. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownFoundayo TRx prescription volume count — Weekly Symphony and IQVIA prescription tracking for Foundayo oral uptake. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in revenue in the first half of 2026.
- · The company's oral obesity drug Foundayo has achieved formulary coverage across major pharmacy benefit managers.
- · Non-GLP-1 therapies in Lilly's portfolio generated 121% revenue growth in Q2 2026.
- · LLY shares declined approximately 7% over the past month.
Public research record
Research framework · page evidenceCompleted event assessment
PBM formulary access driving commercial oral GLP-1 volume adoption
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in revenue in the first half of 2026. | 2026-09-18 |
| Interpretation | PBM formulary access driving commercial oral GLP-1 volume adoption | LLY |
Countercase, invalidators, and sources
Foundayo prescription ramp accelerates in Q3, pushing annualized GLP-1 and oral portfolio revenue toward $60 billion.
- · Foundayo TRx prescription volume count — Weekly Symphony and IQVIA prescription tracking for Foundayo oral uptake.
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? · 2026-09-17
What remains unresolved
- Base path
- PBM coverage delivers steady oral pill adoption while Mounjaro and Zepbound sustain low double-digit quarterly sequential growth.
- Adverse path
- PBM pricing concessions and tiered copay restrictions compress net realized revenue per patient below consensus.
- Supportive path
- Foundayo prescription ramp accelerates in Q3, pushing annualized GLP-1 and oral portfolio revenue toward $60 billion.
- · Foundayo TRx prescription volume count — Weekly Symphony and IQVIA prescription tracking for Foundayo oral uptake.this week
Evidence
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?2026-09-17
“Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales... oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs...”
Supports: Eli Lilly GLP-1 revenue generated $27.7 billion in H1 2026; Foundayo secured major PBM coverage.